Price Vision Group | Indianapolis, IN
Status and phase
Conditions
Treatments
About
This is a Phase IIa study to assess efficacy and safety of STN1010904 ophthalmic suspension (0.03%, and 0.1 %), twice daily dosing when compared to Placebo in subjects diagnosed with Fuchs Endothelial Corneal Dystrophy (FECD). This study will consist of a Screening Period of up to 15 days and an 18-month Double-Masked Treatment Period, including 9 individual visits to the study site.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
80 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Santen Inc Clinical Operations
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal